NR4A1 and breast carcinoma: The Breast Cancer Precision Treatment Committee of the Chinese Medical Doctor Association has issued expert consensus on BRCA1/2 genetic testing and clinical application in Chinese breast cancer patients referring to the international guidelines issued by the National Comprehensive Cancer Network (NCCN) and proposed characteristics of breast cancer patients who should be recommended for BRCA1/2 testing based on clinical risk factors such as age of onset, hormone receptor status and personal or family history of cancer (Wang et al., 2018).